Filing Flows › Phathom Pharmaceuticals (PHAT) › Q2 2026 › vs Q1 2026
Phathom Pharmaceuticals (PHAT) Q2 2026 vs Q1 2026 (quarter over quarter)
Phathom Pharmaceuticals's revenue rose $16.0M (+27%) from $58.3M in Q1 2026 to $74.3M in Q2 2026.
Phathom Pharmaceuticals, Q2 2026: revenue $74.3M (+88% year over year), operating margin -5.3%, net loss $17.6M, operating cash flow −$1.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $74.3M | $58.3M | $16.0M | +27% |
| Net loss | $17.6M | $30.4M | −$12.8M | -42% |
| Costs & expenses | $91.9M | $88.7M | $3.2M | +4% |
| Operating costs | $78.2M | $73.8M | $4.5M | +6% |
| Interest & other, net | $13.6M | $14.9M | −$1.3M | -9% |
| Cost of revenue | $15.1M | $12.0M | $3.1M | +26% |
| Research & development | $7.8M | $7.8M | $42K | +0.5% |
| SG&A | $55.3M | $54.0M | $1.3M | +2% |
| Operating cash sources | $17.6M | $30.4M | −$12.8M | -42% |
| Depreciation & amortization | $114K | $110K | $4K | +4% |
| Share-based compensation | $6.7M | $5.5M | $1.2M | +21% |
| Working capital & other | $8.8M | $9.1M | −$252K | -3% |
| Cash used in operations | $1.9M | $15.6M | −$13.7M | -88% |
| Net loss absorbed | $17.6M | $30.4M | −$12.8M | -42% |
Questions
How much did Phathom Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Phathom Pharmaceuticals's revenue rose $16.0M (+27%) from $58.3M in Q1 2026 to $74.3M in Q2 2026.